期刊文献+

一个新的肿瘤相关基因──CYP2C19 被引量:1

A New Tumor-Related Gene-CYP2C19
下载PDF
导出
摘要 细胞色素P450 2C19(CY2C19)又称为S-美芬妥英羟化酶,它的两个突变型等位基因CYP2C19m1和CYP2C19m2是引起CYP2C19酶活性缺陷的原因,运用等位基因特异扩增法(ASA)对肺癌患者、膀胱癌患者及正常人进行了CYP2C19基因分型研究,以探索CYP2C19酶活性与肺癌、膀胱癌易患性的关系,经过对74例肺癌患者、50例膀胱癌患者和70例对照组的测定。 Cytochrome P450 2C19(CYP2C19, S-mephenytoin hydroxylase) enzyme deficiency was caused by two mutant alleles: CYP2C19ml and CYP2C19m2. An allele-specific amplification based CYP2C19 genotyping method was employed to analyze 74 cases of lung cancer patients, 50 cases of bladder cancer patients and a control group with 70 healthy subjects. It was found that the frequency of poor metabolizers of CYP2C19 was 32.4% in lung cancer group, 4.0% in bladder cancer group and 15.7% in control group. There were extremely statistic differences between control group and experimental groups. Poor metabolisers of CYP2C19 had an increased risk of lung cancer, but had a decreased risk of bladder cancer. It suggested that CYP2C19 is a new tumor-related gene and the enzyme may participate in the inactivation of carcinogens of lung cancer and the activation of procarcinogens of bladder cancer.
出处 《宁波大学学报(理工版)》 CAS 2000年第3期13-15,共3页 Journal of Ningbo University:Natural Science and Engineering Edition
基金 浙江省自然科学基金!(396473)
关键词 CYP2C19基因 肿瘤相关基因 肺癌 膀胱癌 CYP2C19 gene tumor-related gene lung cancer, bladder cancer
  • 相关文献

参考文献12

  • 1Wedlund P J, Aslanian W S,McAllister C B, et al. Frequency of mephenytoin hydroxylation deficiency in a caucasianpopulation:Independence from debrisoquine hydroxylation deficiency[J]. Clin PharmacolTher, 1984, 36(6): 773.
  • 2Wrighton S A, Stevens J C, Becker G W, et al. Isolation and characterization ofhuman liver cytochrome P450 2C19:correlation between 2C19 and S-mephenytoin 4′-hydroxylation[J].Arch of Biochem and Biophys, 1993, 306(1):240.
  • 3de Morais S M F, Wilkinson G R, Blaisdell J, et al. The major genetic defectresponsible for the polymorphism of S-mephenytoin metabolism in humans[J]. J Biol Chem,1994, 269:15 419.
  • 4de Morais S M F, Wilkinson G R, Blaisdell J, et al. Identification of a new geneticdefect responsible for the polymorphism of (s)-mephenytoin metabolism in Japanese[J]. MolPharmacol 1994, 46: 594.
  • 5Caporaso N, Landi M T, Vineis P. Relevance of metabolic polymorphisms to humancarcinogenesis: evaluation of epidemiologic evidence[J]. Pharmacogenetics, 1991, 1:4.
  • 6Nebert D W. Identification of genetic differences in drug metabolism: Prediction ofindividual risk of toxicity on cancer[J]. Hepatology 1991, 14:398.
  • 7Nebert D W. Polymorphism of human CYP2D genes involved in drug metabolism: possiblerelationship to individual cancer risk[J]. Cancer Cell, 1991, 3:93.
  • 8Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high riskindividuals to lung cancer by polymorphisms of the cytochrome P450 |A| gene[J]. FEBS Lett,1990, 263:131.
  • 9Hayashi S, Watanabe J, Nakachi K, et al. Genetic linkage of lung cancer-associatedMsp I polymorphisms with amino acid replacement in the heme-binding region of the humancytochrome P450 |A| gene[J]. J Biochem Tokyo, 1991, 110: 407.
  • 10Uematsu F, Kikuchi H, Motomiya M, et al. Association between restriction fragmentlength polymorphism of the human cytochrome P450IIEl gene and susceptibility to lungcancer[J]. Jpn J Cancer Res, 1991, 82:254.

共引文献2

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部